[A26-19] Ivosidenib (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2026
Project no.:
A26-19
Commission:
Commission awarded on 02.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with newly diagnosed acute myeloid leukaemia with an isocitrate dehydrogenase-1 R132 mutation for whom standard induction chemotherapy is not suitable
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-19
| Project no. | Title | Status |
|---|---|---|
| G23-15 | Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| G23-16 | Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| A26-20 | Ivosidenib (cholangiocarcinoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |